Comprehensive Analysis of Treatment, Disease Burden, and Quality of Life in Patients with Hypoparathyroidism

Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v5i4.3123

Xueyu Zhong, Wenbin Zheng Zheng, Wenfang Xia Xia

Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, Hubei, China

Abstract

Objective: The purpose of this study was to gain insight into the current status of treatment, disease burden, and the impact on the quality of life of patients with hypoparathyroidism (parathyroidism), to assess the effectiveness and limitations of existing treatments, and to explore the patients' need for information about the disease and their expectations of treatment options. Methods: A cross-sectional survey research method was used to collect data on parathyroidism patients' basic information, treatment regimen, frequency of treatment adjustments, treatment costs, clinical symptom control, complications, quality of life, and satisfaction by distributing electronic questionnaires through social media platforms such as WeChat. The questionnaires included patients' personal feelings, treatment outcome scores, disease burden assessment, and needs for healthcare resources. Results: Patients face multiple challenges in the treatment of parathyroidism. Most patients were on a regimen of oral calcium, active vitamin D, and magnesium supplements, but treatment adjustments were frequent, and uncontrolled clinical symptoms were present. Patients generally feel a severe impact on their physical and mental health, with limited work and social activities and low overall quality of life satisfaction. In terms of financial burden, patients suffered high out-of-pocket healthcare costs and had a low evaluation of available treatment resources. Conclusion: Parathyroidism has a significant impact on patients' lives, there are limitations in existing treatment options, and patients are in urgent need of more effective Methods of treatment and more social support. Results provide a basis for improving treatment strategies and quality of life for patients with hypoparathyroidism, pointing out directions for improvement in healthcare policy, healthcare resource allocation, and patient support. (The conclusion of this paper summarizes the main points of the paper and provides readers with clearer information. But it could be more concise and emphasize key points. I think it needs to be rephrased.)

Keywords

hypoparathyroidism; treatment status; disease burden; quality of life; patient needs

References

[1] Khan AA, Rejnmark L, Rubin M, et al. PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism [J]. J Clin Endocrinol Metab, 2022,107(1):e372-e385.
[2] Rejnmark L. Treatment of Hypoparathyroidism by Re-Establishing the Effects of Parathyroid Hormone [J]. Endocrinol Metab (Seoul), 2024,39(2):262-266.
[3] Bjornsdottir S, Ing S, Mitchell DM, et al. Epidemiology and Financial Burden of Adult Chronic Hypoparathyroidism [J]. J Bone Miner Res. 2022,37(12):2602-2614.
[4] van Dijk SPJ, van Driel MHE, van Kinschot CMJ, et al. Management of Postthyroidectomy Hypoparathyroidism and Its Effect on Hypocalcemia-Related Complications: A Meta-Analysis [J]. Otolaryngol Head Neck Surg, 2024,170(2):359-372.
[5] Martin S, Chen K, Harris N, et al. Development of a Patient-Reported Outcome Measure for Chronic Hypoparathyroidism [J]. Adv Ther, 2019,36(8):1999-2009.
[6] Gonçalves CI, Carriço JN, Omar OM, et al. Hypoparathyroidism, deafness and renal dysplasia syndrome caused by a GATA3 splice site mutation leading to the activation of a cryptic splice site [J]. Front Endocrinol (Lausanne). 2023,14:1207425.
[7] Lončar I, van Kinschot CMJ, van Dijk SPJ, et al. Persistent post-thyroidectomy hypoparathyroidism: A multicenter retrospective cohort study [J]. Scand J Surg, 2022,111(2):14574969221107282.
[8] Torre AY, Gómez NL, Abuawad C, et al. Use of parathormone as a predictor of hypoparathyroidism after total thyroidectomy [J]. Cir Cir. 2020,88(1):56-63.
[9] Koimtzis GD, Stefanopoulos L, Giannoulis K, et al. What are the real rates of temporary hypoparathyroidism following thyroidectomy? It is a matter of definition: a systematic review [J]. Endocrine, 2021,73(1):1-7.
[10] Mihai R, Thakker RV. MANAGEMENT OF ENDOCRINE DISEASE: Postsurgical hypoparathyroidism: current treatments and future prospects for parathyroid allotransplantation [J]. Eur J Endocrinol, 2021,184(5):R165-R175.
[11] Clarke BL. Epidemiology and Complications of Hypoparathyroidism [J]. Endocrinology and Metabolism Clinics of North America, 2018,47(4):771-782.
[12] Cusano NE, Bilezikian JP. Signs and Symptoms of Hypoparathyroidism[J]. Endocrinology and Metabolism Clinics of North America,2018,47(4):759-770.
[13] Marcucci G, Cianferotti L, Brandi ML. Clinical presentation and management of hypoparathyroidism [J]. Best Practice & Research Clinical Endocrinology & Metabolism, 2018,32(6):927-939.
[14] Vokes TJ. Quality of Life in Hypoparathyroidism[J]. Endocrinology and Metabolism Clinics of North America,2018,47(4):855-864.
[15] Jeong JY, Song CM, Ji YB, et al. Incidence and risk factors of hypoparathyroidism and hypocalcemia after hemithyroidectomy [J]. Langenbecks Arch Surg, 2023,408(1):298.
[16] Büttner M, Singer S, Taylor K. Quality of life in patients with hypoparathyroidism receiving standard treatment: an updated systematic review [J]. Endocrine, 2024,85(1):80-90.
[17] Fanget F, Demarchi MS, Maillard L, et al. Hypoparathyroidism: Consequences, economic impact, and perspectives. A case series and systematic review[J]. Ann Endocrinol (Paris). 2021 ,82(6):572-581.
[18] Büttner M, Krogh D, Führer D, et al. Hypoparathyroidism - management, information needs, and impact on daily living from the patients' perspective: results from a population-based survey[J]. Hormones (Athens). 2023,22(3):467-476.
[19] Brod M, Waldman LT, Smith A, et al. Living with hypoparathyroidism: development of the Hypoparathyroidism Patient Experience Scale-Impact (HPES-Impact) [J]. Qual Life Res. 2021 ,30(1):277-291.

Copyright © 2024 Xueyu Zhong, Wenbin Zheng Zheng, Wenfang Xia Xia

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License